Replimune Says Path Forward Not Determined for RP1 in Advanced Melanoma

MT Newswires Live

09/18

Replimune (REPL) said Thursday that a path forward for its biologics license application for RP1 plus nivolumab to treat advanced melanoma has not been determined.

The company said it recently completed a type A meeting with the US Food and Drug Administration to discuss the regulator's complete response letter for the RP1 combination therapy.

Replimune said it is assessing the FDA's feedback during the meeting to decide on next steps, adding that it was committed to working with the FDA in finding a path forward for RP1.

The company's shares fell 38% in recent trading Thursday.

Price: 3.54, Change: -2.17, Percent Change: -38.00

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2568403375"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2568403375\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2568403375?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-09-18 21:57","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2568403375","market":"sh","top_or_hot":-1,"title":"Replimune Says Path Forward Not Determined for RP1 in Advanced Melanoma","media":"MT Newswires Live","content":"<html><body><p> Replimune (REPL) said Thursday that a path forward for its biologics license application for RP1 plus nivolumab to treat advanced melanoma has not been determined.</p><p>The company said it recently completed a type A meeting with the US Food and Drug Administration to discuss the regulator's complete response letter for the RP1 combination therapy.</p><p>Replimune said it is assessing the FDA's feedback during the meeting to decide on next steps, adding that it was committed to working with the FDA in finding a path forward for RP1.</p><p>The company's shares fell 38% in recent trading Thursday.</p><p>Price: 3.54, Change: -2.17, Percent Change: -38.00</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Replimune Says Path Forward Not Determined for RP1 in Advanced Melanoma</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nReplimune Says Path Forward Not Determined for RP1 in Advanced Melanoma\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-09-18 21:57</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Replimune (REPL) said Thursday that a path forward for its biologics license application for RP1 plus nivolumab to treat advanced melanoma has not been determined.</p><p>The company said it recently completed a type A meeting with the US Food and Drug Administration to discuss the regulator's complete response letter for the RP1 combination therapy.</p><p>Replimune said it is assessing the FDA's feedback during the meeting to decide on next steps, adding that it was committed to working with the FDA in finding a path forward for RP1.</p><p>The company's shares fell 38% in recent trading Thursday.</p><p>Price: 3.54, Change: -2.17, Percent Change: -38.00</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"FORD","symbol_name":"福沃德工业","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2568403375","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2568403375","pubTimestamp":1758203860,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Replimune  said Thursday that a path forward for its biologics license application for RP1 plus nivolumab to treat advanced melanoma has not been determined.The company said it recently completed a type A meeting with the US Food and Drug Administration to discuss the regulator's complete response letter for the RP1 combination therapy.Replimune said it is assessing the FDA's feedback during the meeting to decide on next steps, adding that it was committed to working with the FDA in finding a path forward for RP1.The company's shares fell 38% in recent trading Thursday.Price: 3.54, Change: -2.17, Percent Change: -38.00","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"FORD":"福沃德工业","BK4145":"电子制造服务","REPL":"Replimune Group Inc.","BK4202":"服装、服饰与奢侈品","BK4139":"生物科技"},"translate_title":"Replimune表示晚期黑色素瘤中RP1的前进道路尚未确定","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"FORD":1.5,"REPL":1},"content_text":"Replimune (REPL) said Thursday that a path forward for its biologics license application for RP1 plus nivolumab to treat advanced melanoma has not been determined.The company said it recently completed a type A meeting with the US Food and Drug Administration to discuss the regulator's complete response letter for the RP1 combination therapy.Replimune said it is assessing the FDA's feedback during the meeting to decide on next steps, adding that it was committed to working with the FDA in finding a path forward for RP1.The company's shares fell 38% in recent trading Thursday.Price: 3.54, Change: -2.17, Percent Change: -38.00","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}